RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis (NCT06328777)
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Who can join: Review the eligibility criteria below.
Location: Yale University — New Haven, Connecticut
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Yale University — New Haven, Connecticut
- Mayo Clinic Florida — Jacksonville, Florida
- Northwestern Memorial Hospital — Chicago, Illinois
- The University of Chicago Medical Center — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic Rochester — Rochester, Minnesota
- Columbia University Irving Medical Center — New York, New York
- University of Rochester — Rochester, New York
- Duke University — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (267) 759-3100
Email: clinicaltrials@cabalettabio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Sclerosis
- KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis — Palo Alto, California
- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) — Scottsdale, Arizona
- Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial — Charleston, South Carolina
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis — Scottsdale, Arizona
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis — New York, New York
- Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis — Houston, Texas
Explore by condition: All Systemic Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.